GRI Bio(GRI) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Cash runway expected to fund operations through Q3 2025 LA JOLLA, CA, May 15, 2025 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the quarter ended March 31, 2025 and provided a corporate update. "We continue to make very encouraging progress with our ongoing Phase 2a trial ...